Published in Br J Cancer on June 22, 2010
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol (2015) 1.81
Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma. BMC Cancer (2016) 1.41
Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol (2011) 1.25
Management of thymic tumors: a European perspective. J Thorac Dis (2014) 0.87
Targeted therapy for advanced thymic tumors. J Thorac Oncol (2010) 0.87
Response to nab-paclitaxel and nedaplatin in a heavily-metastatic thymic carcinoma: A case report. Oncol Lett (2015) 0.83
KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer. J Cancer Res Clin Oncol (2013) 0.82
Stereotactic ablative radiotherapy with CyberKnife for advanced thymic carcinoma: a case report. Curr Oncol (2015) 0.80
KRAS, EGFR, PDGFR-α, KIT and COX-2 status in carcinoma showing thymus-like elements (CASTLE). Diagn Pathol (2014) 0.78
Novel biologic therapies for thymic epithelial tumors. Front Oncol (2014) 0.77
Emerging treatment options for patients with recurrent advanced thymic epithelial tumors. Onco Targets Ther (2012) 0.76
Epithelial thymic tumours in paediatric age: a report from the TREP project. Orphanet J Rare Dis (2011) 0.76
Chemotherapy and prognosis in advanced thymic carcinoma patients. Clinics (Sao Paulo) (2015) 0.75
Rare frequency of gene variation and survival analysis in thymic epithelial tumors. Onco Targets Ther (2016) 0.75
Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene. BMC Cancer (2017) 0.75
Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. Onco Targets Ther (2014) 0.75
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors. J Thorac Oncol (2016) 0.75
Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations. Int J Clin Oncol (2015) 0.75
[Thymus cancers : A clinical observation]. Pathologe (2016) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98
Sunitinib: from rational design to clinical efficacy. J Clin Oncol (2007) 7.26
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 4.29
Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov (2007) 4.27
BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res (2003) 4.17
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A (2009) 2.66
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol (2008) 2.59
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol (2009) 2.27
Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol (2007) 1.71
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol (2006) 1.67
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther (2006) 1.64
Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys (2004) 1.53
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med (2008) 1.47
Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer (2008) 1.21
Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med (2004) 1.19
Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. Ann Thorac Surg (2009) 1.14
Thymoma and thymic carcinoma: therapeutic approaches. Clin Lung Cancer (2004) 1.11
Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol (2009) 1.07
Surgical treatment of thymic tumors. Semin Thorac Cardiovasc Surg (2005) 1.00
Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol (2008) 1.00
Role of chemotherapy in the management of advanced thymic tumors. Semin Thorac Cardiovasc Surg (2005) 0.94
Emergency surgery in the era of molecular treatment of solid tumours. Lancet Oncol (2009) 0.92
Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer (2008) 0.90
Dasatinib induces a response in malignant thymoma. J Clin Oncol (2006) 0.86
Advanced pediatric inoperable thymus carcinoma (type C thymoma): case report on a novel therapeutic approach. J Pediatr Hematol Oncol (2007) 0.80
Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med (1998) 3.45
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol (2010) 3.40
The crystal structure of dimeric kinesin and implications for microtubule-dependent motility. Cell (1997) 3.17
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res (1996) 2.86
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2000) 2.73
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71
Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J Biol Chem (1994) 2.61
Information technology in complex health services: organizational impediments to successful technology transfer and diffusion. J Am Med Inform Assoc (1997) 2.52
An L-type calcium-channel gene mutated in incomplete X-linked congenital stationary night blindness. Nat Genet (1998) 2.48
Analysis of a 24-kilodalton protein associated with the polyhydroxyalkanoic acid granules in Alcaligenes eutrophus. J Bacteriol (1995) 2.41
Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem (2001) 2.32
Review article: Herbal hepatotoxicity--an update on traditional Chinese medicine preparations. Aliment Pharmacol Ther (2014) 2.19
The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood (2001) 2.15
Bidirectional reaction steps in metabolic networks: II. Flux estimation and statistical analysis. Biotechnol Bioeng (1997) 2.11
A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med (1994) 2.11
Microkeratome-assisted posterior keratoplasty. J Cataract Refract Surg (2001) 2.09
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer (1993) 2.08
Resection of liver metastases in colorectal cancer--competitive analysis of treatment results in synchronous versus metachronous metastases. Eur J Surg Oncol (1990) 2.07
Clostridium aceticum (Wieringa), a microorganism producing acetic acid from molecular hydrogen and carbon dioxide. Arch Microbiol (1981) 2.01
Considerations on the structure and biochemistry of bacterial polyhydroxyalkanoic acid inclusions. Can J Microbiol (1995) 1.97
Purification, some properties and quaternary structure of the D-ribulose 1,5-diphosphate carboxylase of Alcaligenes eutrophus. Arch Microbiol (1976) 1.96
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer (2008) 1.88
Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science (1985) 1.88
Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology (2010) 1.88
Measurements of scattered light on a microchip flow cytometer with integrated polymer based optical elements. Lab Chip (2004) 1.86
Lessons from a failed information systems initiative: issues for complex organisations. Int J Med Inform (1999) 1.77
Sagittula stellata gen. nov., sp. nov., a lignin-transforming bacterium from a coastal environment. Int J Syst Bacteriol (1997) 1.75
Ataxia, delayed dentition and hypomyelination: a novel leukoencephalopathy. Neuropediatrics (2007) 1.75
X-ray structure of motor and neck domains from rat brain kinesin. Biochemistry (1997) 1.71
Advertising and sales. J Am Vet Med Assoc (1991) 1.68
Caecal-diverticulitis: a rare differential diagnosis for right-sided lower abdominal pain. Colorectal Dis (2003) 1.67
Primary mouse hepatocytes for systems biology approaches: a standardized in vitro system for modelling of signal transduction pathways. Syst Biol (Stevenage) (2006) 1.63
Molecular systematics of bats of the genus Myotis (Vespertilionidae) suggests deterministic ecomorphological convergences. Mol Phylogenet Evol (2001) 1.63
Simplified stepwise management of primary spontaneous pneumothorax: a pilot study. Eur Respir J (2006) 1.62
Major salivary gland function in primary Sjögren's syndrome and its relationship to clinical features. J Rheumatol (1990) 1.61
Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol (2010) 1.59
Idiotype identity in a MALT-type lymphoma and B cells in Helicobacter pylori associated chronic gastritis. Lab Invest (1994) 1.58
Microbulbifer hydrolyticus gen. nov., sp. nov., and Marinobacterium georgiense gen. nov., sp. nov., two marine bacteria from a lignin-rich pulp mill waste enrichment community. Int J Syst Bacteriol (1997) 1.56
Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol (2000) 1.53
Mitochondrial DNA (mtDNA) reveals that female Bechstein's bats live in closed societies. Mol Ecol (2000) 1.53
Barefoot-shod running differences: shoe or mass effect? Int J Sports Med (2007) 1.53
Purification and characterization of a 14-kilodalton protein that is bound to the surface of polyhydroxyalkanoic acid granules in Rhodococcus ruber. J Bacteriol (1994) 1.52
Airway management during cardiopulmonary resuscitation--a comparative study of bag-valve-mask, laryngeal mask airway and combitube in a bench model. Resuscitation (1999) 1.51
Formation of intracytoplasmic lipid inclusions by Rhodococcus opacus strain PD630. Arch Microbiol (1996) 1.51
Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol (2003) 1.49
Identification of the region of a 14-kilodalton protein of Rhodococcus ruber that is responsible for the binding of this phasin to polyhydroxyalkanoic acid granules. J Bacteriol (1995) 1.48
Thymoma. Curr Opin Oncol (2000) 1.47
Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer (2002) 1.46
Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction. Br J Surg (2012) 1.46
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Procalcitonin as a parameter of disease severity and risk of mortality in patients with Plasmodium falciparum malaria. J Infect Dis (2001) 1.44
Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol (2006) 1.44
Estimate of the maximal daily dietary intake of butylated hydroxyanisole and butylated hydroxytoluene in The Netherlands. Food Chem Toxicol (1990) 1.43
Extreme sex-biased dispersal in the communally breeding, nonmigratory Bechstein's bat (Myotis bechsteinii). Mol Ecol (2002) 1.42
Purification and characterization of the poly(hydroxyalkanoic acid) synthase from Chromatium vinosum and localization of the enzyme at the surface of poly(hydroxyalkanoic acid) granules. Eur J Biochem (1994) 1.42
Plain and complex flagella of Pseudomonas rhodos: analysis of fine structure and composition. J Bacteriol (1974) 1.40
A randomised crossover comparison of mouth-to-face-shield ventilation and mouth-to-pocket-mask ventilation by surf lifeguards in a manikin. Anaesthesia (2014) 1.40
APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol (1993) 1.39
Conservation of infectivity in purified fibrillary extracts of scrapie-infected hamster brain after sequential enzymatic digestion or polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A (1990) 1.38
[Comparison of results of daily blood pressure self-monitoring and general practice monitoring within the scope of a study assessing treatment of hypertension with quinapril]. Wien Med Wochenschr (1992) 1.38
Is genome mapping the way to improve Canadians' health? Can J Public Health (1991) 1.38
The accuracy of free-hand cup positioning--a CT based measurement of cup placement in 105 total hip arthroplasties. Int Orthop (2004) 1.38
Saliva inhibits HIV-1 infectivity. J Am Dent Assoc (1988) 1.36
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol (2011) 1.36
Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood (2000) 1.35
Image reconstructions of microtubules decorated with monomeric and dimeric kinesins: comparison with x-ray structure and implications for motility. J Cell Biol (1998) 1.35
[The induced production of bacteriocin and bacteriophage by the BP6K-N-5 strain of "Clostridium perfringens" (author's transl)]. Ann Microbiol (Paris) (1975) 1.35
Subunit Composition and Glycosidic Activities of the Cellulase Complex from Clostridium thermocellum JW20. Appl Environ Microbiol (1990) 1.34
Iron supplemented formula milk related to reduction in psychomotor decline in infants from inner city areas: randomised study. BMJ (1999) 1.34
Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol (2009) 1.34
A simple and effective method for inactivating virus infectivity in formalin-fixed tissue samples from patients with Creutzfeldt-Jakob disease. Neurology (1990) 1.33
Mucocutaneous lymph node syndrome (MLNS) in the continental United States. Pediatrics (1976) 1.32
Familial translocation with partial trisomy of 13 and 22: evidence that specific regions of chromosomes 13 and 22 are responsible for the phenotype of each trisomy. J Med Genet (1977) 1.30
Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer (2008) 1.29
Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg (2000) 1.29
Salmonella in turtles imported to Israel from Louisiana. JAMA (1986) 1.28
Biochemical and histologic determinants in the prognosis of neuroblastoma. Cancer (1973) 1.27
Increased bacterial density at the edge of antibiotic zones of inhibition. J Bacteriol (1966) 1.27
Isolation and characterization of a bacteriophage tail-like bacteriocin from a strain of Rhizobium. J Virol (1972) 1.25
Immunocytochemical localization of carbon monoxide oxidase in Pseudomonas carboxydovorans. The enzyme is attached to the inner aspect of the cytoplasmic membrane. J Biol Chem (1984) 1.25
Micromorphology of Gram-negative hydrogen bacteria. II. Cell envelope, membranes, and cytoplasmic inclusions. Arch Microbiol (1977) 1.23
NCCN Practice Guidelines for Breast Cancer. Oncology (Williston Park) (2000) 1.22
Acquired renal cysts in uremic patients--in vivo demonstration by computed tomography. Clin Nephrol (1980) 1.22
Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr (1995) 1.20
Defining the mycoplasma 'cytoskeleton': the protein composition of the Triton X-100 insoluble fraction of the bacterium Mycoplasma pneumoniae determined by 2-D gel electrophoresis and mass spectrometry. Microbiology (2001) 1.19
8-Eth-oxy-3-(4-isopropyl-benzyl-idene)-6-methyl-chroman-4-one. Acta Crystallogr Sect E Struct Rep Online (2007) 1.18
Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT? Eur Radiol (2011) 1.18
Gain in strength and muscular balance after balance training. Int J Sports Med (2001) 1.18
Micromorphology of Gram-negative hydrogen bacteria. I. Cell morphology and flagellation. Arch Microbiol (1977) 1.18
Structure of a fast kinesin: implications for ATPase mechanism and interactions with microtubules. EMBO J (2001) 1.18
The hemolytic-uremic syndrome: a study of renal pathologic alterations. Am J Pathol (1969) 1.18
The combined effect of smoking and coffee drinking on LDL and HDL cholesterol. Circulation (1979) 1.17
ROS1 fusions in Chinese patients with non-small-cell lung cancer. Ann Oncol (2013) 1.17
Neonatal hepatitis and biliary atresia associated with trisomy 17-18 syndrome. N Engl J Med (1969) 1.17
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol (2004) 1.17
Light- and electron-microscopic histochemistry of Fabry's disease. Am J Pathol (1981) 1.17